# US 2010/0169987 A1 · Animal model simulating neurologic disease

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2010/0169987 A1
- Document ID: US20100169987A1
- Status: Published application
- Kind: A1
- Application number: 12/478,957
- Filed: 2009-06-05
- Published: 2010-07-01
- Earliest claimed: 2003-03-12
- Assignees: Georgetown University; Samaritan Pharmaceuticals, Inc.
- Inventors: Laurent Lecanu; Vassilios Papadopulos; Janet Greeson
- Web page: https://patentgrep.com/patent/US20100169987A1

## CPC

- A01K 67/027: New or modified breeds of vertebrates
- A61K 49/0008: {Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure}
- A01K 2227/105: Murine
- A01K 2267/0312: Animal model for Alzheimer's disease
- A01K: ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present invention relates to the development of a pharmacological non-human animal model that associates memory loss to histopathological features found in the brain of a subject having Alzheimer's Disease. In one embodiment, a four-week continuous infusion of a Fe2+, Aβ42 and buthionine sulfoximine (FAB) solution in the left ventricle of young adult Long-Evans rats induced memory impairment accompanied by increased hyperphosphorylated Tau protein levels in cerebrospinal fluid. Brains from treated animals displayed neuritic plaques, tangles, neuronal loss, astrogliosis and microgliosis in hippocampus and cortex. The present invention may be utilized in evaluating preventive, therapeutic and diagnostic means for neurologic diseases.

## Claims

### Claim 1

A non-human animal having a neurologic disease induced by the process of:
perfusing the non-human animal with a pharmacologically effective amount of a combination of an Aβ compound, at least one pro-oxidative compound, and at least one anti-oxidant inhibitor, wherein the perfusion produces impaired performance of the animal in memory and learning tests and induces abnormal neuropathology in a brain of the animal, wherein said impaired performance and abnormal neuropathology are in comparison with control non-human animals.

### Claim 2 (depends on 1)

The non-human animal of claim 1, wherein the Aβ compound comprises Aβ42.

### Claim 3 (depends on 1)

The non-human animal of claim 1, wherein the Aβ compound comprises a peptide fragment of Aβ42.

### Claim 4 (depends on 3)

The non-human animal of claim 3, wherein the peptide fragment of Aβ42 comprises at least one of Aβ1-40 or Aβ24-35.

### Claim 5 (depends on 1)

The non-human animal of claim 1, wherein the Aβ compound comprises a peptidomimetic that mimicks Aβ42.

### Claim 6 (depends on 1)

The non-human animal of claim 1, wherein the at least one pro-oxidative compound is selected from the group consisting of ferrous sulfate, copper sulfate, cobalt sulfate, manganese sulfate, and zinc sulfate.

### Claim 7 (depends on 1)

The non-human animal of claim 1, wherein the at least one pro-oxidative compound comprises ferrous sulfate.

### Claim 8 (depends on 1)

The non-human animal of claim 1, wherein the at least one anti-oxidant inhibitor comprises buthionine sulfoximine.

### Claim 9 (depends on 1)

The non-human animal of claim 1, wherein the process further comprises perfusing the non-human animal with an effective amount of a phosphatase inhibitor.

### Claim 10 (depends on 9)

The non-human animal of claim 9, wherein the phosphatase inhibitor is selected from the group consisting of okadaic acid, 1-nor-okadaone, bioallethrin, calycullin A, cantharidic acid, cantharidin, cypermethrin, deltamethrin, endothall, endothall thioanhydride, fenvalerate, okadol, permethrin, phenylarsine oxide, pyrophosphate, sodium fluoride, and vanadate.

### Claim 11 (depends on 9)

The non-human animal of claim 9, wherein the phophatase inhibitor comprises okadaic acid.

### Claim 12 (depends on 1)

The non-human animal of claim 1, wherein the process further comprises perfusing the non-human animal with an effective amount of a pro-inflammatory compound.

### Claim 13 (depends on 12)

The non-human animal of claim 12, wherein the pro-inflammatory compound is selected from the group consisting of TNF-α, IL-6, and IL-1b.

### Claim 14 (depends on 12)

The non-human animal of claim 12, wherein the pro-inflammatory compound comprises TNF-α.

### Claim 15

A method for inducing a neurologic disease in a non-human animal, comprising:
perfusing the non-human animal with a pharmacologically effective amount of a combination of an Aβ compound, at least one pro-oxidative compound, and at least one anti-oxidant inhibitor.

### Claim 16 (depends on 15)

The method of claim 15, wherein the Aβ compound comprises Aβ42.

### Claim 17 (depends on 15)

The method of claim 15, wherein the Aβ compound comprises a peptide fragment of Aβ42.

### Claim 18 (depends on 17)

The method of claim 17, wherein the peptide fragment of Aβ42 comprises at least one of Aβ1-40 or Aβ24-35.

### Claim 19 (depends on 15)

The method of claim 15, wherein the Aβ compound comprises a peptidomimetic that mimicks Aβ42.

### Claim 20 (depends on 15)

The method of claim 15, wherein the at least one pro-oxidative compound is selected from the group consisting of ferrous sulfate, copper sulfate, cobalt sulfate, manganese sulfate, and zinc sulfate.

### Claim 21 (depends on 15)

The method of claim 15, wherein the at least one pro-oxidative compound comprises ferrous sulfate.

### Claim 22 (depends on 15)

The method of claim 15, wherein the at least one anti-oxidant inhibitor comprises buthionine sulfoximine.

### Claim 23 (depends on 15)

The method of claim 15, further comprising perfusing the non-human animal with an effective amount of a phosphatase inhibitor.

### Claim 24 (depends on 23)

The method of claim 23, wherein the phosphatase inhibitor is selected from the group consisting of okadaic acid, 1-nor-okadaone, bioallethrin, calycullin A, cantharidic acid, cantharidin, cypermethrin, deltamethrin, endothall, endothall thioanhydride, fenvalerte, okadol, permethrin, phenylarsine oxide, pyrophosphate, sodium fluoride, and vanadate.

### Claim 25 (depends on 23)

The method of claim 23, wherein the phophatase inhibitor comprises okadaic acid.

### Claim 26 (depends on 15)

The method of claim 15, further comprising perfusing the non-human animal with an effective amount of a pro-inflammatory compound.

### Claim 27 (depends on 27)

The method of claim 27, wherein the pro-inflammatory compound is selected from the group consisting of TNF-α, IL-6, and IL-1b.

### Claim 28 (depends on 27)

The method of claim 27, wherein the pro-inflammatory compound comprises TNF-α.

### Claim 29

A method of screening for an agent that ameliorates symptoms of a neurologic disease, said method comprising:
comparing performance on memory and learning tests of a first non-human animal contacted with the agent with that of a second non-human animal not contacted with the agent, wherein the first and said second non-human animals have been co-infused with a pharmacologically effective amount of Aβ, at least one pro-oxidative compound, and at least one anti-oxidant inhibitor wherein the co-infusion produces impaired performance on the memory and learning tests and abnormal neuropathology in a brain of the first and second non-human animals, wherein the impaired performance and the abnormal neuropathology are in comparison with control non-human animals, whereby an agent which ameliorates the symptoms is identified by superior performance of said first non-human animal in comparison with the second non-human animal on the memory and learning tests.

### Claim 30

A method for screening for an agent useful for treating a neurologic disease, said method comprising:
comparing performance on memory and learning tests of a first non-human animal contacted with the agent with that of a second non-human animal not contacted with the agent, wherein the first and said second non-human animals have been co-infused with a pharmacologically effective amount of Aβ and at least one pro-oxidative compound, and at least one anti-oxidant inhibitor, wherein the co-infusion produces impaired performance on the memory and learning tests and abnormal neuropathology in a brain of the first and second non-human animals, wherein the impaired performance and the abnormal neuropathology are compared with control non-human animals; and comparing neuropathology in the brain of the first and the second non-human animal when said first non-human animal exhibits superior performance on the memory and learning tests compared with the second non-human animal, whereby an agent which is useful for treating a neurologic disease is identified by a decrease in neuropathologic findings in the first non-human animal in comparison with the second non-human animal.
